To further investigate whether MAPK signaling pathways, specifically ERK1/2, JNK1/2, and p38 kinases, regulate AREG upregulation in Visfatin-treated HCT-116 CRC cells, the cells were pretreated with DMSO (vehicle), PD98059 (an ERK1/2 inhibitor at 25 μM), SP600125 (a JNK1/2 inhibitor at 20 μM), or SB203580 (a p38 inhibitor at 10 μM) for 30 min. The gene discussed is MAPK3; the disease is colorectal carcinoma.